Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07421544 · ClinicalTrials.gov registry record · Phase 4
Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
A Phase 4 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Not yet
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT07421544: Clinical Trial Phase 4 study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
NCT07421544 is a Phase 4 study that has not yet begun recruiting, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07421544, a Phase 4 study, has not yet begun recruiting, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.
Primary Outcome
Circle One: 1. Very Much Improved 2. Much Improved 3. Improved 4. No Change 5. Worse
Interventions
- OTHER Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 4 |
What is known before NCT07421544 opens enrollment
NCT07421544 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid is the first listed.
NCT07421544 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07421544 about?
NCT07421544 is a clinical study titled "Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines". Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over...
What is the current status of trial NCT07421544?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-03-01. Estimated completion is 2026-07-01.
What interventions are being tested in trial NCT07421544?
The interventions under investigation include: Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (OTHER).
Who is sponsoring clinical trial NCT07421544?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07421544's enrollment target sits among peer trials
100 770th of 2000 higher than 1,148 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI